ENO1: A Protein Involved in DNA Repair and Signaling (G2023)

Target Name: ENO1

NCBI ID: G2023

ENO1

ENO1: A Protein Involved in DNA Repair and Signaling

ENO1 (Endonuclease 1) is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and kidney. It is a key enzyme in the DNA repair pathway, which is responsible for repairing damage to DNA that can occur due to factors such as radiation, chemicals, or genetic mutations. ENO1 plays a crucial role in the regulation of DNA repair processes, and is therefore a potential drug target or biomarker.

The DNA repair pathway is a critical network of biological processes that helps to ensure the stability and integrity of genetic information. When DNA is damaged or broken, the cell needs to repair the damage to ensure that the genetic information is preserved. ENO1 is involved in the first step of this process, known as homologous recombination. This is a process by which the cell matches a broken DNA segment with a compatible piece of DNA. The resulting homologous recombinant DNA is then repaired and integrated into the cell's genome.

ENO1 is a protein that is composed of 254 amino acids and has a calculated molecular mass of 31.1 kDa. It is expressed in a variety of tissues, including the liver, spleen, and kidney, and is also found in the cytoplasm of cultured cells. ENO1 is a member of the NHEJ (Nucleotide Excision Repair) family, which is responsible for repairing a wide range of DNA damage types.

ENO1 has been shown to play a role in a variety of biological processes, including DNA repair, cellular signaling, and inflammation. For example, ENO1 has been shown to be involved in the regulation of the DNA damage response (DDR), a process that is triggered when DNA is damaged or broken. ENO1 has been shown to play a role in the loading of DNA repair factors onto the damaged strand, which is critical for efficient repair.

In addition to its role in DNA repair, ENO1 has also been shown to be involved in a variety of signaling pathways. For example, ENO1 has been shown to be involved in the regulation of the TGF-β pathway, a process that is involved in cell growth, differentiation, and inflammation. ENO1 has also been shown to be involved in the regulation of the NF-kappa-B pathway, a process that is involved in inflammation and immune response.

ENO1 has also been shown to have potential as a drug target or biomarker. For example, ENO1 has been shown to be a potential drug target for a variety of diseases, including cancer, where ENO1 has been shown to be involved in the regulation of DNA repair and cellular signaling. In addition, ENO1 has also been shown to be a potential biomarker for a variety of diseases, including cancer, where ENO1 levels can be increased due to DNA damage.

In conclusion, ENO1 is a protein that is involved in a variety of biological processes, including DNA repair, cellular signaling, and inflammation. It is also a potential drug target or biomarker, and has been shown to be involved in the regulation of DNA repair, TGF-β pathway, NF-kappa-B pathway and others. Further research is needed to fully understand the role of ENO1 in these processes and its potential as a drug target or biomarker.

Protein Name: Enolase 1

Functions: Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate (PubMed:29775581, PubMed:1369209). In addition to glycolysis, involved in various processes such as growth control, hypoxia tolerance and allergic responses (PubMed:2005901, PubMed:10802057, PubMed:12666133, PubMed:29775581). May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons (PubMed:12666133). Stimulates immunoglobulin production (PubMed:1369209)

The "ENO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets